share_log

6-K: Report of foreign private issuer (related to financial reporting)

6-K: Report of foreign private issuer (related to financial reporting)

6-K：外国发行人报告（业绩相关）
美股sec公告 ·  05/24 17:08
Moomoo AI 已提取核心信息
Apollomics Inc., a biopharmaceutical company, has established an 'At the Market' sales program, entering into a Sales Agreement with Cantor Fitzgerald & Co. on May 24, 2024. The agreement allows for the sale of up to $19 million of the company's Class A ordinary shares. The sales will be conducted as needed in the market, without any obligation for the company to sell a specific number of shares. The Sales Agent will receive a 3.0% commission on the gross proceeds from the sales. Both Apollomics and the Sales Agent have the right to terminate the agreement under certain conditions, including a significant adverse change in Apollomics' business or financial condition. The offering will conclude once the total sales reach $19 million or if the Sales Agreement is terminated. This move is part of Apollomics' efforts to raise capital through its effective registration statement on Form F-3.
Apollomics Inc., a biopharmaceutical company, has established an 'At the Market' sales program, entering into a Sales Agreement with Cantor Fitzgerald & Co. on May 24, 2024. The agreement allows for the sale of up to $19 million of the company's Class A ordinary shares. The sales will be conducted as needed in the market, without any obligation for the company to sell a specific number of shares. The Sales Agent will receive a 3.0% commission on the gross proceeds from the sales. Both Apollomics and the Sales Agent have the right to terminate the agreement under certain conditions, including a significant adverse change in Apollomics' business or financial condition. The offering will conclude once the total sales reach $19 million or if the Sales Agreement is terminated. This move is part of Apollomics' efforts to raise capital through its effective registration statement on Form F-3.
生物制药公司Apollomics Inc. 已经制定了 “在市场上” 的销售计划，并于2024年5月24日与坎托·菲茨杰拉德公司签订了销售协议。该协议允许出售该公司高达1900万美元的A类普通股。销售将根据市场需要进行，公司没有任何义务出售特定数量的股票。销售代理将从销售总收益中获得3.0％的佣金。Apollomics和销售代理都有权在某些条件下终止协议，包括Apollomics的业务或财务状况发生重大不利变化。一旦总销售额达到1900万美元或销售协议终止，此次发行将结束。此举是Apollomics通过其在F-3表格上的有效注册声明筹集资金的努力的一部分。
生物制药公司Apollomics Inc. 已经制定了 “在市场上” 的销售计划，并于2024年5月24日与坎托·菲茨杰拉德公司签订了销售协议。该协议允许出售该公司高达1900万美元的A类普通股。销售将根据市场需要进行，公司没有任何义务出售特定数量的股票。销售代理将从销售总收益中获得3.0％的佣金。Apollomics和销售代理都有权在某些条件下终止协议，包括Apollomics的业务或财务状况发生重大不利变化。一旦总销售额达到1900万美元或销售协议终止，此次发行将结束。此举是Apollomics通过其在F-3表格上的有效注册声明筹集资金的努力的一部分。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息